Poland Picks Protein-based COVID-19 Vaccine as the Only Option

Novavax Inc. recently announced its updated protein-based COVID-19 vaccine is now the only COVID-19 vaccine option available in the Republic of Poland.

Doses were distributed by the appropriate Polish authorities in 2023 and made available for this season's vaccination campaign. 

Novavax's vaccine is available in Polato to prevent COVID-19 in individuals aged 12 and older.

In Poland, from January 2020 to early December 2023, there have been 6,573,698 confirmed cases of COVID-19, with 119,839 related deaths.

As of October 2023, a total of 58,240,570 doses of various COVID-19 vaccines had been administered in Poland.

We are pleased that our updated vaccine is available in time for the upcoming Christmas and winter holidays, wrote the company on December 11, 2023. We are honored to support the Polish government and the country's healthcare workers in helping to protect Polish citizens and their loved ones against COVID-19.

Recent non-clinical data showed that Novavax's updated COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax's vaccine-induced neutralizing antibody responses to subvariants BA.2.86, EG.5.1, FL.1.5.1, and XBB.1.16.6 as well as CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6.

These data indicate that Novavax's vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants.

As of December 14, 2023, Sweden and Italy have authorized Novavx's updated vaccine. Throughout the recent pandemic, Novavax COVID-19 Vaccines have been authorized in Europe, the U.S., the U.K., and numerous other countries under various brands.